Comparative Modeling to Inform Cervical Cancer Control Policies

比较模型为宫颈癌控制政策提供信息

• 批准号: 10471425
• 负责人: Ruanne Vanessa Barnabas
• 金额: $ 124.37万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-08 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10471425
• 关键词: Address; Adolescent; Australia; CD4 Lymphocyte Count; Cancer Burden; Cancer Control; Cancer Intervention and Surveillance Modeling Network; Cervical; Cervical Cancer Screening; Clinical Data; Clinical Research; Clinical Trials; Collaborations; Comparative Carcinogenesis; Cost Effectiveness Analysis; Country; Data; Decision Making; Development; Disease; Disease Outcome; Effectiveness; Ensure; Evaluation; Guidelines; HIV; Health; Health Benefit; Health Policy; Human Papilloma Virus Vaccination; Human Papilloma Virus-Related Malignant Neoplasm; Human Papillomavirus; Infection; Information Dissemination; Kenya; Knowledge; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Modeling; Netherlands; New Mexico; North Dakota; Outcome; Policies; Policy Maker; Population; Preventative vaccination; Prevention strategy; Process; Public Health; Reporting; Research Personnel; Risk; Route; Series; South Africa; Technology; Testing; Time; Uganda; United States; Update; Vaccinated; Vaccination; Vaccines; Woman; base; cancer health disparity; cervical cancer prevention; cervical carcinogenesis; co-infection; cohort; comparative; comparative effectiveness; cost; cost effective; cost effectiveness; disparity reduction; effectiveness evaluation; evidence base; human model; improved; innovation; low and middle-income countries; mathematical model; new technology; programs; scale up; screening; screening guidelines; sexually transmitted virus; tool; vaccination strategy; working group

Project Summary Despite successful cervical cancer screening in the United States (US), over 13,000 women develop and 4,000 women die from cervical cancer each year. The discovery of human papillomavirus (HPV) as the necessary cause of cervical cancer precipitated a surge of new evidence and development of innovative HPV-based technologies, both screening and prophylactic vaccination, that have allowed for significant changes in our approach to cervical cancer control over the past two decades. These new technologies represent tremendous opportunities for effective, equitable, and efficient cervical cancer programs in the US but also pose significant challenges for decision-making. Given the limited availability of outcomes data for new screening and vaccination approaches from empirical studies, policy-makers have become uniquely reliant on mathematical modeling to provide a synthesized evidence base for decision-making for cervical cancer control strategies. These models can be used to integrate the most up-to-date data, extrapolate short-term findings into long-term outcomes, and evaluate what-if scenarios that would otherwise be impractical or infeasible to conduct in clinical studies. The proposed CISNET project will represent the continued, productive collaboration of five independent modeling groups from the US, Australia, and the Netherlands that will leverage a series of state- of-the-art mathematical models of HPV and cervical carcinogenesis for comparative modeling. We will pursue analyses related to the impact of newly-revised screening and HPV vaccination guidelines, the comparative effectiveness of forthcoming screening and HPV vaccination strategies and approaches, the optimal routes for reducing cervical cancer disparities, the potential for cervical cancer elimination in the US, and optimal screening and vaccination strategies in women living with HIV. Our efforts will also involve wide dissemination of findings to various stakeholders to increase transparency and confidence in model-based analyses.

项目总结